Elsevier Unveils ScienceDirect AI in 2025 to Revolutionize Research Efficiency
Revance's Botox Rival Receives USFDA Nod
By Indu Tyagi Ketan , 19 October, 2022
DaxibotulinumtoxinA (Daxxify), Revance's long-awaited Botox rival, has officially received FDA approval, as the company is now gearing up to establish its brand. Daxxify is an intravenous neuromodulator similar to Botox; its novel peptide exchange technology temporarily eases the moderate to severe glabellar (frown) lines.
The trials revealed that a single injection had a significant anti-wrinkle impact on durational effects were proven in phase 3 trials with 4,200 treatments and 2,700 patients. The chief differentiator for Daxxify is its endurance; it can last six months and has even proven effective for up to nine months in some individuals, vis-a-vis Botox injections that last only for three months.
Daxxify was initially scheduled to receive FDA approval in November 2020, but the epidemic slowed inspection. After visiting Revance's production facility, inspectors discovered quality control and record-keeping issues. The FDA then issued Revance a detailed response letter in October of last year. Soon after, the FDA approved the changes in July after Revance resolved all five problems mentioned in the Complete Response Letter.
In a separate report, Goldman Sachs predicted that Revance's Daxxify will cost about 30% more than its competitors, even though pricing has not yet been made public. This cost considers the extended value proposition for both doctors and patients. Revance's stock rose 18% in September post the FDA's approval, which is expected to end Botox's long-standing dominance in the aesthetics industry.
FDA Approves DaxibotulinumtoxinA (Daxxify)
Latest News
Elsevier Unveils ScienceDirect AI in 2025 to Revolutionize Research Efficiency
In March 2025, Elsevier launched ScienceDirect AI, a world-renowned leader in science and health information science. This state-of-the-art generative AI tool can potentially transform the industry with its revolutionary advances in research. This…
EV Revolution: Battery Prices Drop Below USD 100/kWh Amid China's Dominance of the Market in 2025
The global electric vehicle (EV) industry has reached a pivotal milestone. The average price of lithium-ion battery packs has dropped below the USD 100 per kilowatt-hour (kWh) threshold, a benchmark long considered critical for achieving price parity…
China Accelerates Push for Domestic EV Chips Amid Global Trade Tensions in 2025
In 2025, China will focus on self-sufficiency in high-tech industries by further integrating domestically produced semiconductor chips into the country\'s electric vehicle (EV) industry. By doing so, China aims to reduce reliance on foreign…
General Motors Leverages AI to Revolutionize Manufacturing in 2025
GM will implement artificial intelligence (AI) in the company's facilities in 2025 to improve safety, quality, and efficiency. This appears to be another strategic initiative from GM aimed at innovation and operational improvement.
At GM, one of the…
Honda and Renesas Collaborate for Next-Gen Software-Defined Vehicles in 2025
In January 2025, Honda Motor Co., Ltd. and Renesas Electronics Corporation declared a strategic collaboration to create a high-performance system on a chip (SoC) designed for Software Defined Vehicles (SDVs). This cooperation is intended to bolster…
Indu Tyagi Ketan
Chief Strategy Officer
Latest News
EV Revolution: Battery Prices Drop Below USD 100/kWh Amid China's Dominance of the Market in 2025
China Accelerates Push for Domestic EV Chips Amid Global Trade Tensions in 2025
General Motors Leverages AI to Revolutionize Manufacturing in 2025
Honda and Renesas Collaborate for Next-Gen Software-Defined Vehicles in 2025
